Ashland Global Holdings Inc. provides specialty chemical solutions worldwide. The company's Specialty Ingredients segment offers products, technologies, and resources for solving formulation and product-performance challenges. It provides solutions using natural, synthetic, and semisynthetic polymers derived from cellulose ethers, vinyl pyrrolidones, acrylic polymers, polyester and polyurethane-based adhesives, and plant and seed extracts. This segment offers its solutions for the pharmaceutical companies; makers of personal care products, food, and beverages; makers of nutraceuticals and supplements; manufacturers of paint, coatings, and construction materials; packaging and converting markets; and oilfield service companies. Its Intermediates and Solvents produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone that are used as chemical intermediates in the production of engineering polymers and polyurethanes, as well as specialty process solvents used in electronics, pharmaceuticals, water filtration membranes, and others. The company was formerly known as Ashland Inc. and changed its name to Ashland Global Holdings Inc. in September 2016. Ashland Global Holdings Inc. was founded in 1924 and is based in Wilmington, Delaware.
IPO Year:
Exchange: NYSE
Website: ashland.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2024 | $90.00 → $89.00 | Underweight → Neutral | JP Morgan |
| 4/11/2024 | $100.00 → $112.00 | Equal Weight → Overweight | Wells Fargo |
| 3/14/2024 | $100.00 → $126.00 | Hold → Buy | Jefferies |
| 3/1/2024 | $108.00 | Outperform | Wolfe Research |
| 6/29/2023 | Outperform → In-line | Evercore ISI | |
| 6/26/2023 | $109.00 → $90.00 | Outperform → Market Perform | BMO Capital Markets |
| 2/2/2023 | $104.00 → $105.00 | Neutral → Underweight | JP Morgan |
| 9/12/2022 | $120.00 | Outperform | Credit Suisse |
| 2/3/2022 | $125.00 → $127.00 | Buy | Mizuho |
| 1/24/2022 | $133.00 → $120.00 | Outperform | BMO Capital |
WILMINGTON, Del., Nov. 14, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on December 15, 2024, to stockholders of record at the close of business on December 1, 2024. As of October 31, 2024, there were 47,109,326 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coa
Financial results for fourth-quarter fiscal 20241 Sales of $522 million, up one percent from the prior-year quarterSold nutraceuticals business to Turnspire Capital Partners LLCPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization initiatives reduced overall sales by approximately $24 million or five percent versus the prior-year quarterIncome from continuing operations of $19 million, or $0.39 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $61 million, or $1.26 per diluted shareAdjusted EBITDA of $124 million, up 68 percent from the prior-year quarterAdjusted EBITDA below
WILMINGTON, Del., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its fourth-quarter fiscal 2024 earnings release at approximately 5 p.m. ET on Wednesday, November 6, 2024. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Thursday, November 7. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerKevin Willis, senior vice president and chief fin
WILMINGTON, Del., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on September 15, 2024, to stockholders of record at the close of business on September 1, 2024. As of July 31, 2024, there were 48,832,846 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural co
Sales of $544 millionNet income (including discontinued operations) of $6 million, or $0.12 per diluted shareIncome from continuing operations of $31 million, or $0.60 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $75 million, or $1.49 per diluted shareAdjusted EBITDA of $139 million, up five percent from the prior-year quarterCash flows provided by operating activities of $128 million; ongoing free cash flow2 of $112 millionRepurchased 1.3 million shares; $770 million remaining under existing authorization WILMINGTON, Del., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced financial results1 for the third
WILMINGTON, Del., July 17, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its third-quarter earnings release at approximately 5 p.m. ET on Tuesday, August 6, 2024. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Wednesday, August 7. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerKevin Willis, senior vice president and chief financial officer Wi
WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock which represents a five percent increase from the previous quarter. The dividend is payable on June 15, 2024, to stockholders of record at the close of business on June 1, 2024. As of April 30, 2024, there were 50,128,349 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environment, social and governance (ESG). The company serves customers in a wide range of consum
Sales of $575 million, down five percent from the prior-year quarterNet income (including discontinued operations) of $120 million, or $2.39 per diluted shareIncome from continuing operations of $121 million, or $2.40 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $64 million, or $1.27 per diluted shareAdjusted EBITDA of $126 millionCash flows provided by operating activities of $54 million; ongoing free cash flow2 of $4 million WILMINGTON, Del., April 30, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced financial results1 for the second quarter of fiscal year 2024, which ended March 31, 2024, and issued its outloo
WILMINGTON, Del., April 18, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its second-quarter earnings release at approximately 5 p.m. ET on Tuesday, April 30, 2024. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, May 1. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerKevin Willis, senior vice president and chief financial officer Will
Sales of $473 million, down 10 percent from the prior-year quarterNet income (including discontinued operations) of $26 million, or $0.51 per diluted shareIncome from continuing operations of $28 million, or $0.54 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $23 million, or $0.45 per diluted shareAdjusted EBITDA of $70 millionCash flows provided by operating activities of $201 million; ongoing free cash flow2 of $66 million WILMINGTON, Del., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced financial results1 for the first quarter of fiscal year 2024, which ended December 31, 2023, and issued its ou
WILMINGTON, Del., Nov. 14, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on December 15, 2024, to stockholders of record at the close of business on December 1, 2024. As of October 31, 2024, there were 47,109,326 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coa
WILMINGTON, Del., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) will host a strategy update event for analysts and investors on Tuesday, December 10, 2024, in New York City. The company will provide an in-depth review of Ashland's strategic priorities, key initiatives and financial objectives while emphasizing a proactive approach to market uncertainty in fiscal year 2025. The event will include presentations and prepared remarks from members of Ashland's executive team, as well as breakout sessions for in-person attendees. There will be an opportunity for both live and webcast attendees to ask questions during moderated Q&A sessions. Participants include: Guillermo Novo, ch
Financial results for fourth-quarter fiscal 20241 Sales of $522 million, up one percent from the prior-year quarterSold nutraceuticals business to Turnspire Capital Partners LLCPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization initiatives reduced overall sales by approximately $24 million or five percent versus the prior-year quarterIncome from continuing operations of $19 million, or $0.39 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $61 million, or $1.26 per diluted shareAdjusted EBITDA of $124 million, up 68 percent from the prior-year quarterAdjusted EBITDA below
WILMINGTON, Del., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its fourth-quarter fiscal 2024 earnings release at approximately 5 p.m. ET on Wednesday, November 6, 2024. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Thursday, November 7. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerKevin Willis, senior vice president and chief fin
D.A. Davidson & Co. announced today that it served as exclusive financial advisor to Turnspire Capital Partners LLC ("Turnspire") on an asset-backed credit facility to finance Turnspire's acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918901821/en/D.A. Davidson & Co. announced today that it served as exclusive financial advisor to Turnspire Capital Partners LLC on an asset-backed credit facility to finance Turnspire's acquisition of Pharmachem Innovations, LLC, the former nutraceuticals bus
Wilmington, Del., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Ashland has accelerated the application of the company's new super wetting technology platform announced last September. The company has commercialized easy-wet™ 300 n super wetting agent for corn, soy and wheat as well as watermelon, florals and other produce including bananas, lettuce, tomatoes and more. Successful field trials and customer pilots over the last year validates Ashland's strategy and demonstrates the company's commitment to quickly scaling high-performance, innovative and sustainable technologies. Easy-wet™ 300 n is a biodegradable, nonionic, silicone-free, better processing and low-foaming wetting agent for crop f
WILMINGTON, Del., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced it has completed the sale of its nutraceuticals business to an affiliate of Turnspire Capital Partners LLC ("Turnspire") effective August 30, 2024. The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed. "The nutraceuticals business has a strong portfolio of proprietary ingredients, formulation and manufacturing capabilities," said Guillermo Novo, chair and chief executive officer, Ashland. "I want
Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu
Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio
WILMINGTON, Del., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on September 15, 2024, to stockholders of record at the close of business on September 1, 2024. As of July 31, 2024, there were 48,832,846 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural co
10-K - ASHLAND INC. (0001674862) (Filer)
8-K - ASHLAND INC. (0001674862) (Filer)
8-K - ASHLAND INC. (0001674862) (Filer)
8-K - ASHLAND INC. (0001674862) (Filer)
144 - ASHLAND INC. (0001674862) (Subject)
10-Q - ASHLAND INC. (0001674862) (Filer)
8-K - ASHLAND INC. (0001674862) (Filer)
11-K - ASHLAND INC. (0001674862) (Filer)
11-K - ASHLAND INC. (0001674862) (Filer)
8-K - ASHLAND INC. (0001674862) (Filer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
BMO Capital analyst John McNulty maintains Ashland (NYSE:ASH) with a Market Perform and raises the price target from $97 to $105.
The transaction is expected to close in the calendar third quarter 2024, subject to the satisfaction of customary closing conditions. Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies, as well as custom formulation and contract manufacturing capabilities for the nutrition market, from four production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico.
JP Morgan analyst Jeffrey Zekauskas maintains Ashland (NYSE:ASH) with a Underweight and raises the price target from $88 to $90.
UBS analyst Joshua Spector maintains Ashland (NYSE:ASH) with a Buy and raises the price target from $114 to $116.
3 analysts have expressed a variety of opinions on Ashland (NYSE:ASH) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $116.0, a high estimate of $126.
Mizuho analyst John Roberts maintains Ashland (NYSE:ASH) with a Buy and raises the price target from $101 to $110.
Ashland (NYSE:ASH) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.14 by 11.4 percent. This is a 11.19 percent decrease over earnings of $1.43 per share from the same period last year. The company reported quarterly sales of $575.000 million which beat the analyst consensus estimate of $574.638 million by 0.06 percent. This is a 4.64 percent decrease over sales of $603.000 million the same period last year.
In the last three months, 4 analysts have published ratings on Ashland (NYSE:ASH), offering a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 1 1 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 1 1 0 Analysts have set 12-month price targets for Ashland, revealing an average target of $106.5, a high estimate of $126.00, and a low estimate of $88.00. Observing a 21.71% increase, the current average has risen fr
Wells Fargo analyst Michael Sison upgrades Ashland (NYSE:ASH) from Equal-Weight to Overweight and raises the price target from $100 to $112.
Jim Minicucci, senior vice president strategy, mergers and acquisitions, and portfolio management, Ashland, becomes senior vice president and general manager, personal care, Ashland. Effective April 15, 2024, Dago Caceres, will become vice president and general manager, specialty additives, Ashland. The company will announce the new leader for strategy, mergers and acquisitions, and portfolio management soon.
SC 13G - ASHLAND INC. (0001674862) (Subject)
SC 13G/A - ASHLAND INC. (0001674862) (Subject)
SC 13D/A - ASHLAND INC. (0001674862) (Subject)
SC 13G/A - ASHLAND INC. (0001674862) (Subject)
SC 13G - ASHLAND INC. (0001674862) (Subject)
SC 13G/A - ASHLAND INC. (0001674862) (Subject)
SC 13G/A - ASHLAND INC. (0001674862) (Subject)
SC 13G/A - ASHLAND INC. (0001674862) (Subject)
SC 13G/A - ASHLAND INC. (0001674862) (Subject)
SC 13D/A - ASHLAND GLOBAL HOLDINGS INC (0001674862) (Subject)
JP Morgan upgraded Ashland from Underweight to Neutral and set a new price target of $89.00 from $90.00 previously
Wells Fargo upgraded Ashland from Equal Weight to Overweight and set a new price target of $112.00 from $100.00 previously
Jefferies upgraded Ashland from Hold to Buy and set a new price target of $126.00 from $100.00 previously
Wolfe Research initiated coverage of Ashland with a rating of Outperform and set a new price target of $108.00
Evercore ISI downgraded Ashland from Outperform to In-line
BMO Capital Markets downgraded Ashland from Outperform to Market Perform and set a new price target of $90.00 from $109.00 previously
JP Morgan downgraded Ashland from Neutral to Underweight and set a new price target of $105.00 from $104.00 previously
Credit Suisse initiated coverage of Ashland with a rating of Outperform and set a new price target of $120.00
Mizuho reiterated coverage of Ashland Global Holdings with a rating of Buy and set a new price target of $127.00 from $125.00 previously
BMO Capital reiterated coverage of Ashland Global Holdings with a rating of Outperform and set a new price target of $120.00 from $133.00 previously
Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu
Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio
WILMINGTON, Del., May 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) is announcing the appointment of Ashish K. Kulkarni to its Board of Directors. Kulkarni is the CEO of Kebotix, a startup company focused on commercializing artificial intelligence methods into new material commercialization. He is the former executive vice president and chief innovation officer, GAF, former chief technology and innovation officer, Avantor and former chief technology and innovation officer, Celanese Corporation. He will serve on the Board's Environmental, Health, Safety and Quality, and Compensation Committees, effective May 6, 2024. Prior to Celanese, Kulkarni held leadership positions at United Te
WILMINGTON, Del., April 15, 2024 (GLOBE NEWSWIRE) -- Effective today, Ashland Inc. (NYSE:ASH) has announced the appointment of Scott A. Tozier, strategic advisor to the CEO and former executive vice president and chief financial officer of Albemarle Corporation to its Board of Directors. Tozier will serve on the Board's Audit Committee and Environmental, Health, Safety and Quality Committee, each also effective April 15, 2024. Prior to Albemarle, Tozier held several leadership positions at Honeywell International, Inc. and served on the Board of Directors for Garrett Motion, Inc. Tozier is an experienced global executive with strong industry leadership in financial management, mergers and
WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023. Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua
WILMINGTON, Del., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced that its board of directors has approved the appointment of Robin Lampkin as senior vice president, general counsel and secretary. Lampkin joined Ashland in 1991 and has held various roles throughout her 32-year tenure including tort litigation and global environmental regulatory and remediation. As Ashland's chief compliance officer, she has deep corporate governance experience partnering with a variety of stakeholders on global regulatory compliance, training programs, policy administration and ethics investigations. Lampkin is a strategic advisor for global teams for product safety, sustainab
WILMINGTON, Del., June 26, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced the appointment of Sergio Pedreiro, former chief operating officer, Revlon, to its Board of Directors, effective July 1, 2023. Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annual Shareholders Meeting in January 2024. Ihlenfeld is the former senior vice president, 3M Company and member of the environmental, health, safety and quality committee and the governance and nominating committee. Cummins is the former chief executive officer of Ciba Specialty Chemicals and the chair of
WILMINGTON, Del., June 10, 2022 (GLOBE NEWSWIRE) -- Ashland Global Holdings Inc. (NYSE:ASH) today announced the appointment of two new directors to its Board as of July 1, 2022: Steve Bishop, former chief executive officer, Procter and Gamble (P&G) consumer health care, and Suzan Harrison, former president, Colgate-Palmolive global oral care. William Dempsey who has served as a director since 2016, and Ricky Sandler, who joined the board in 2020 have decided not to stand for re-election at Ashland's Annual Shareholders Meeting in January 2023. Dempsey is the former executive vice president, global pharmaceuticals, Abbott Laboratories and the current chair of the Board's governance and n
MOREHEAD, Ky., Feb. 09, 2022 (GLOBE NEWSWIRE) -- AppHarvest, Inc. (NASDAQ:APPH, APPHW))), a leading AgTech company, public benefit corporation and Certified B Corp building some of the world's largest high-tech indoor farms to grow affordable, nutritious fruits and vegetables at scale while providing good jobs in Appalachia, announced today the unanimous appointment of J. Kevin Willis as a director of the company, as chair of the board's audit committee and as a member of the nominating and corporate governance committee, effective Feb. 19. Willis currently serves as the Senior Vice President and Chief Financial Officer of Ashland (NYSE:ASH), a global specialty materials company, and join